Clinical trials: Stage II and III
Melanoma (Skin)
Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members
RATIONALE: Studying the genes expressed in samples of blood from patients with cancer and their family members may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00346008
- Testing
- mutation analysis, high performance liquid chromatography, laboratory biomarker analysis
- Where
- Iceland
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Iceland Genomics Corporation
Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia.
- Trial name
- NCT00447993
- Testing
- Low Dose NT-501, High Dose NT-501
- Where
- 11 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neurotech Pharmaceuticals
Multiple Myeloma
BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- IMGN901 (NCT00346255)
- Testing
- BB-10901
- Where
- 8 sites in United States, Argentina
- Volunteers
- 37 people
- Sponsor
- ImmunoGen, Inc.
Glioblastoma
Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
This is a multi-center, phase II/III, open-label, randomized, parallel and standard chemoradiation-controlled study where eligible subjects will be randomized at 1:1 ratio to receive control treatment or study treatment.
- Trial name
- NCT03008148
- Testing
- CCRT, Temozolomide, Siroquine
- Where
- 2 sites in Taiwan
- Volunteers
- 288 people
- Sponsor
- Johnpro Biotech, Inc.
Liver Cirrhosis, Chronic Hepatitis C
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
This study evaluated the clinical response of the efficacy and safety of the combination therapy of peginterferon alfa-2a and ribavirin, compared with an antiviral treatment-free group in CHC patients with compensated LC.
- Trial name
- NCT00304551
- Testing
- peginterferon alfa-2a 180μg, peginterferon alfa-2a 90μg, ribavirin
- Where
- 8 sites in Japan
- Volunteers
- 180 people
- Sponsor
- Chugai Pharmaceutical
Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS)
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
This is a phase II/III multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of BAT4406F injection in patients with Minimal Change Disease/Focal Segmental Glomerulosclerosis
- Trial name
- NCT07499700
- Testing
- BAT4406F
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Bio-Thera Solutions
Migraine
Acute Treatment Trial in Adult Subjects With Migraines
The purpose of the study is to evaluate the safety and efficacy of three different intranasal dose levels of zavegepant (BHV-3500), relative to placebo, in the acute treatment of moderate to severe migraine.
- Trial name
- NCT03872453
- Testing
- Zavegepant, Intranasal Aptar Pharma Unit Dose System
- Where
- 82 sites in United States
- Volunteers
- 2,154 people
- Sponsor
- Pfizer
Melanoma
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma
This is a study of an investigational cancer vaccine called GRN-1201. Treatment with the GRN-1201 vaccine is a type of immunotherapy.
- Trial name
- NCT02696356
- Testing
- GRN-1201
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- BrightPath Biotherapeutics
Recurrent or Metastatic Breast Cancer
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
To compare and evaluate the efficacy and safety of Liporaxel® solution (oral paclitaxel) and Taxol® (IV paclitaxel) on recurrent or metastatic breast cancer.
- Trial name
- OPTIMAL (NCT03315364)
- Testing
- Oral paclitaxel, Paclitaxel injection
- Where
- 51 sites in Bulgaria, China and 3 more
- Volunteers
- 549 people
- Sponsor
- Daehwa Pharmaceutical Co., Ltd.
Active Psoriatic Arthritis
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .
- Trial name
- NCT04314531
- Testing
- TILD
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 296 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Head and Neck Neoplasms, Neoplasm Recurrence, Local
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent…
- Conditions
- Head and Neck Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
- Trial name
- NCT00401323
- Testing
- docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU)
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 568 people
- Sponsor
- Sanofi
Lung Cancer
Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004202
- Testing
- carboplatin, chemotherapy, efaproxiral
- Where
- 16 sites in United States, Canada
- Sponsor
- Spectrum Pharmaceuticals, Inc
Cancer-related Fatigue, Neutropenia, Malignant
PG2 Breast Cancer Evaluation in Adjuvant Medicine Study
Adjuvant chemotherapy usually is recommended after surgery for breast cancer patients who are at significant risk for disseminated disease. Chemotherapy has been demonstrated to reduce the risk of breast cancer recurrence.
- Trial name
- PG2 BEAM (NCT03314805)
- Testing
- Astragalus polysaccharides 500 mg, EC Chemotherapy
- Where
- 5 sites in Taiwan
- Volunteers
- 67 people
- Sponsor
- PhytoHealth Corporation
Heart Failure, Congestive
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
- Trial name
- RELAX-AHF (NCT00520806)
- Testing
- Relaxin
- Where
- 3 sites in United States, Israel
- Volunteers
- 1,161 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Non-Small-Cell Lung
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based…
- Trial name
- NCT03456063
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Nab-paclitaxel, Pemetrexed
- Where
- 117 sites in United States, Australia and 22 more
- Volunteers
- 453 people
- Sponsor
- Hoffmann-La Roche
Lupus Nephritis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with…
- Trial name
- POSTERITY (NCT05039619)
- Testing
- Obinutuzumab, Mycophenolate Mofetil, Acetaminophen/paracetamol
- Where
- 44 sites in United States, Brazil and 10 more
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Influenza
Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005
The objectives of the study are to assess the immunogenicity and safety among three different lots of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
- Trial name
- NCT00161811
- Testing
- Vero Cell-derived Influenza Vaccine, Egg cell-derived Influenza Vaccine
- Where
- 4 sites in Austria, Germany
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III Non Ambulant
Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
Assess the efficacy and the safety of olesoxime in SMA type 2 or type 3 non ambulant patients aged 3-25 years
- Trial name
- NCT01302600
- Testing
- Olesoxime
- Where
- 22 sites in Belgium, France and 5 more
- Volunteers
- 165 people
- Sponsor
- Hoffmann-La Roche
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
Hypertension, Pulmonary
Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension (PAH).
- Trial name
- NCT00540436
- Testing
- GSK1325760A
- Where
- 15 sites in Japan
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline